Which has higher valuation and earnings, DCGO or BDSX?

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.16 -$182.40M -$1.91 N/A Biodesix $88.50M 2.79 -$35.26M -$4.06 N/A

Is DCGO or BDSX more profitable?

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Biodesix -33.26% -2,101.40% -35.65%

Does the media refer more to DCGO or BDSX?

In the previous week, Biodesix had 1 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Biodesix and 2 mentions for DocGo. Biodesix's average media sentiment score of 1.79 beat DocGo's score of 0.93 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better valuation & earnings, XGN or DCGO?

Exagen has higher earnings, but lower revenue than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exagen $66.57M 1.72 -$19.95M -$0.89 N/A DocGo $322.20M 0.16 -$182.40M -$1.91 N/A

Is XGN or DCGO more profitable?

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Exagen -29.49% -94.37% -28.96% DocGo -62.23% -44.09% -29.14%

Which has preferable valuation and earnings, PARK or DCGO?

Park Dental Partners has higher earnings, but lower revenue than DocGo. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Park Dental Partners $248.15M 0.38 -$360K N/A N/A DocGo $322.20M 0.16 -$182.40M -$1.91 N/A

Does the media favor PARK or DCGO?

In the previous week, Park Dental Partners had 1 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Park Dental Partners and 2 mentions for DocGo. Park Dental Partners' average media sentiment score of 1.12 beat DocGo's score of 0.93 indicating that Park Dental Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Park Dental Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, DCGO or PIII?

P3 Health Partners has higher revenue and earnings than DocGo. P3 Health Partners is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.16 -$182.40M -$1.91 N/A P3 Health Partners $1.46B 0.06 -$147.95M -$38.60 N/A

Is DCGO or PIII more profitable?

P3 Health Partners has a net margin of -8.57% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat P3 Health Partners' return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% P3 Health Partners -8.57% -302.33% -19.99%

Does the media prefer DCGO or PIII?

In the previous week, P3 Health Partners had 2 more articles in the media than DocGo. MarketBeat recorded 4 mentions for P3 Health Partners and 2 mentions for DocGo. P3 Health Partners' average media sentiment score of 1.26 beat DocGo's score of 0.93 indicating that P3 Health Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive P3 Health Partners 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend BNR or DCGO?

DocGo has a consensus price target of $2.38, suggesting a potential upside of 357.61%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

DocGo (DCGO) Competitors

$0.52 +0.03 (+5.33%)

Closing price 04:00 PM Eastern

Extended Trading

$0.54 +0.02 (+3.66%)

As of 04:29 PM Eastern

Compare

DCGO vs. BDSX, XGN, PARK, PIII, and BNR

Should you buy DocGo stock or one of its competitors? MarketBeat compares DocGo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DocGo include Biodesix (BDSX), Exagen (XGN), Park Dental Partners (PARK), P3 Health Partners (PIII), and Burning Rock Biotech (BNR). These companies are all part of the "healthcare" industry.

How does DocGo compare to Biodesix?

DocGo (NASDAQ:DCGO) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.16	-$182.40M	-$1.91	N/A
Biodesix	$88.50M	2.79	-$35.26M	-$4.06	N/A

In the previous week, Biodesix had 1 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Biodesix and 2 mentions for DocGo. Biodesix's average media sentiment score of 1.79 beat DocGo's score of 0.93 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Biodesix has a net margin of -33.26% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Biodesix	-33.26%	-2,101.40%	-35.65%

DocGo currently has a consensus target price of $2.38, suggesting a potential upside of 357.61%. Biodesix has a consensus target price of $28.33, suggesting a potential upside of 19.04%. Given DocGo's higher probable upside, equities analysts clearly believe DocGo is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

56.4% of DocGo shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 3.8% of DocGo shares are held by insiders. Comparatively, 23.2% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

DocGo has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Biodesix has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market.

Summary

DocGo and Biodesix tied by winning 8 of the 16 factors compared between the two stocks.

How does DocGo compare to Exagen?

Exagen (NASDAQ:XGN) and DocGo (NASDAQ:DCGO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Exagen currently has a consensus target price of $9.11, suggesting a potential upside of 91.81%. DocGo has a consensus target price of $2.38, suggesting a potential upside of 357.61%. Given DocGo's higher probable upside, analysts plainly believe DocGo is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Exagen has a beta of 2.01, indicating that its share price is 101% more volatile than the broader market. Comparatively, DocGo has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.

In the previous week, Exagen and Exagen both had 2 articles in the media. Exagen's average media sentiment score of 1.93 beat DocGo's score of 0.93 indicating that Exagen is being referred to more favorably in the media.

Company	Overall Sentiment
Exagen	Very Positive
DocGo	Positive

75.3% of Exagen shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 10.4% of Exagen shares are held by company insiders. Comparatively, 3.8% of DocGo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Exagen has higher earnings, but lower revenue than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.72	-$19.95M	-$0.89	N/A
DocGo	$322.20M	0.16	-$182.40M	-$1.91	N/A

Exagen has a net margin of -29.49% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.49%	-94.37%	-28.96%
DocGo	-62.23%	-44.09%	-29.14%

Summary

Exagen beats DocGo on 12 of the 16 factors compared between the two stocks.

How does DocGo compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Park Dental Partners had 1 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Park Dental Partners and 2 mentions for DocGo. Park Dental Partners' average media sentiment score of 1.12 beat DocGo's score of 0.93 indicating that Park Dental Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Park Dental Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.4% of DocGo shares are owned by institutional investors. 10.6% of Park Dental Partners shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Park Dental Partners presently has a consensus target price of $21.75, suggesting a potential upside of 3.28%. DocGo has a consensus target price of $2.38, suggesting a potential upside of 357.61%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Park Dental Partners has higher earnings, but lower revenue than DocGo.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$248.15M	0.38	-$360K	N/A	N/A
DocGo	$322.20M	0.16	-$182.40M	-$1.91	N/A

Park Dental Partners has a net margin of 0.00% compared to DocGo's net margin of -62.23%. Park Dental Partners' return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
DocGo	-62.23%	-44.09%	-29.14%

Summary

Park Dental Partners beats DocGo on 10 of the 14 factors compared between the two stocks.

How does DocGo compare to P3 Health Partners?

DocGo (NASDAQ:DCGO) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends.

P3 Health Partners has higher revenue and earnings than DocGo. P3 Health Partners is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.16	-$182.40M	-$1.91	N/A
P3 Health Partners	$1.46B	0.06	-$147.95M	-$38.60	N/A

In the previous week, P3 Health Partners had 2 more articles in the media than DocGo. MarketBeat recorded 4 mentions for P3 Health Partners and 2 mentions for DocGo. P3 Health Partners' average media sentiment score of 1.26 beat DocGo's score of 0.93 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
P3 Health Partners	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DocGo currently has a consensus price target of $2.38, suggesting a potential upside of 357.61%. P3 Health Partners has a consensus price target of $14.00, suggesting a potential upside of 18.44%. Given DocGo's stronger consensus rating and higher possible upside, research analysts clearly believe DocGo is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

P3 Health Partners has a net margin of -8.57% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat P3 Health Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
P3 Health Partners	-8.57%	-302.33%	-19.99%

DocGo has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, P3 Health Partners has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

56.4% of DocGo shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 3.8% of DocGo shares are owned by insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

DocGo and P3 Health Partners tied by winning 8 of the 16 factors compared between the two stocks.

How does DocGo compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 3.8% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DocGo has a consensus price target of $2.38, suggesting a potential upside of 357.61%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Burning Rock Biotech has a net margin of -11.57% compared to DocGo's net margin of -62.23%. Burning Rock Biotech's return on equity of -10.98% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.98%	-7.33%
DocGo	-62.23%	-44.09%	-29.14%

Burning Rock Biotech has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, DocGo has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

In the previous week, DocGo had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 2 mentions for DocGo and 1 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.89 beat DocGo's score of 0.93 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Burning Rock Biotech	Very Positive
DocGo	Positive

Burning Rock Biotech has higher earnings, but lower revenue than DocGo. Burning Rock Biotech is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$77.16M	1.12	-$7.92M	-$0.82	N/A
DocGo	$322.20M	0.16	-$182.40M	-$1.91	N/A

Summary

Burning Rock Biotech beats DocGo on 9 of the 16 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$51.25M	$9.35B	$6.85B	$12.43B
Dividend Yield	N/A	1.66%	2.67%	6.11%
P/E Ratio	-0.27	25.93	25.82	24.36
Price / Sales	0.16	16.88	549.91	101.32
Price / Cash	8.86	14.92	29.09	36.93
Price / Book	0.41	5.99	10.97	6.50
Net Income	-$182.40M	$179.69M	$3.58B	$336.61M
7 Day Performance	-2.70%	5.81%	3.00%	0.89%
1 Month Performance	-21.12%	4.99%	0.67%	-0.36%
1 Year Performance	-67.56%	16.44%	36.72%	31.12%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	3.202 of 5 stars	$0.52 +5.3%	$2.38 +360.2%	-69.3%	$50.97M	$322.20M	N/A	3,568	Gap Up
BDSX Biodesix	4.0581 of 5 stars	$16.81 flat	$26.50 +57.6%	+366.2%	$174.15M	$88.50M	N/A	220	Positive News High Trading Volume
XGN Exagen	4.3314 of 5 stars	$4.54 flat	$9.25 +103.7%	-34.6%	$109.69M	$66.57M	N/A	220	Positive News
PARK Park Dental Partners	2.6736 of 5 stars	$18.24 flat	$21.75 +19.2%	N/A	$82.45M	$244.49M	N/A	1,208	Short Interest Decrease
PIII P3 Health Partners	2.8153 of 5 stars	$10.75 flat	$14.00 +30.2%	+77.6%	$77.83M	$1.46B	N/A	500	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors

DCGO vs. BDSX, XGN, PARK, PIII, and BNR

How does DocGo compare to Biodesix?

Summary

How does DocGo compare to Exagen?

Summary

How does DocGo compare to Park Dental Partners?

Summary

How does DocGo compare to P3 Health Partners?

Summary

How does DocGo compare to Burning Rock Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO vs. The Competition

DocGo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DocGo (DCGO) Competitors

DCGO vs. BDSX, XGN, PARK, PIII, and BNR

How does DocGo compare to Biodesix?

Which has higher valuation and earnings, DCGO or BDSX?

Does the media refer more to DCGO or BDSX?

Is DCGO or BDSX more profitable?

Do analysts prefer DCGO or BDSX?

Do insiders and institutionals hold more shares of DCGO or BDSX?

Which has more risk and volatility, DCGO or BDSX?

Summary

How does DocGo compare to Exagen?

Do analysts prefer XGN or DCGO?

Which has more risk and volatility, XGN or DCGO?

Does the media prefer XGN or DCGO?

Do institutionals and insiders hold more shares of XGN or DCGO?

Which has better valuation & earnings, XGN or DCGO?

Is XGN or DCGO more profitable?

Summary

How does DocGo compare to Park Dental Partners?

Does the media favor PARK or DCGO?

Do insiders & institutionals hold more shares of PARK or DCGO?

Do analysts recommend PARK or DCGO?

Which has preferable valuation and earnings, PARK or DCGO?

Is PARK or DCGO more profitable?

Summary

How does DocGo compare to P3 Health Partners?

Which has better earnings and valuation, DCGO or PIII?

Does the media prefer DCGO or PIII?

Do analysts prefer DCGO or PIII?

Is DCGO or PIII more profitable?

Which has more volatility and risk, DCGO or PIII?

Do institutionals and insiders hold more shares of DCGO or PIII?

Summary

How does DocGo compare to Burning Rock Biotech?

Do insiders & institutionals hold more shares of BNR or DCGO?

Do analysts recommend BNR or DCGO?

Is BNR or DCGO more profitable?

Which has more volatility and risk, BNR or DCGO?

Does the media prefer BNR or DCGO?

Which has better earnings & valuation, BNR or DCGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO vs. The Competition

DocGo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools